World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
35919
World Ranking
13922
National Ranking
7066

Bayard L. Powell publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Bayard L. Powell sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 436 publications — 46th percentile

46% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Bayard L. Powell D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Bayard L. Powell sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Bayard L. Powell is affiliated with Wake Forest University in the United States and has an extensive body of research primarily focused on the study of hematologic malignancies. Their work spans multiple disciplines including medicine, biochemistry, genetics, and molecular biology, with a specialized concentration on hematology.

Their research addresses critical topics within leukemia, such as acute myeloid leukemia, acute lymphoblastic leukemia, and related blood disorders. Specific areas of investigation include hematopoietic stem cell transplantation, myeloproliferative neoplasms, neutropenia in cancer infections, and the role of histone deacetylase inhibitors. These research interests are reflected in the following main topics:

  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Histone Deacetylase Inhibitors Research
  • Chronic Myeloid Leukemia Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Neutropenia and Cancer Infections
  • Hematopoietic Stem Cell Transplantation

Among recent publications by Bayard L. Powell are:

  • "Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma" (2020), published in the Journal of Clinical Oncology
  • "Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/ KMT2A" (2020), published in Proceedings of the National Academy of Sciences
  • "Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial" (2022), published in Blood
  • "Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia" (2020), published in Cancer Discovery
  • "Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study" (2023), published in Leukemia

Powell collaborates frequently with several other researchers, including:

  • Jonathan E. Kolitz
  • Krzysztof Mrózek
  • Deedra Nicolet
  • Richard M. Stone
  • Ann-Kathrin Eisfeld

Publications by Bayard L. Powell are commonly found in a select group of scientific journals. These venues include:

  • Blood
  • Blood Advances
  • Leukemia
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)

The breadth of publications spans over 165 works in medicine and 60 in biochemistry, genetics, and molecular biology, with a significant focus on hematology (85 publications), followed by molecular biology (49), public health (24), oncology (16), and genetics (15).

Best Publications

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

    Lewis R. Silverman;Erin P. Demakos;Bercedis L. Peterson;Alice B. Kornblith

  • Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

    Mayer Rj;Davis Rb;Schiffer Ca;Berg Dt

  • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

    Alan List;Gordon Dewald;John Bennett;Aristotle Giagounidis

  • Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

    R. Coleman Lindsley;Brenton G. Mar;Emanuele Mazzola;Peter V. Grauman

  • IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

    Guido Marcucci;Kati Maharry;Yue-Zhong Wu;Michael D. Radmacher

  • Platelet Transfusion for Patients With Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*

    Charles A. Schiffer;Kenneth C. Anderson;Charles L. Bennett;Steven Bernstein

  • Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia

    Richard M. Stone;Deborah T. Berg;Stephen L. George;Richard K. Dodge

  • Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study

    Alice B. Kornblith;James E. Herndon;Lewis R. Silverman;Erin P. Demakos

  • MicroRNA expression in cytogenetically normal acute myeloid leukemia

    Guido Marcucci;Michael D. Radmacher;Michael D. Radmacher;Kati Maharry;Kati Maharry;Krzysztof Mrózek

  • Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720

    Maria R. Baer;Stephen L. George;Richard K. Dodge;Kieran L. O'Loughlin

  • Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.

    Bayard L. Powell;Barry Moser;Wendy Stock;Robert E. Gallagher

  • Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

    Heiko Becker;Guido Marcucci;Kati Maharry;Michael D. Radmacher

  • Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study

    Guido Marcucci;Krzysztof Mrózek;Amy S. Ruppert;Kati Maharry

  • Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study

    Guido Marcucci;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  • TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

    Klaus H. Metzeler;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  • Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia

    Heidi D. Klepin;Ann M. Geiger;Janet A. Tooze;Stephen B. Kritchevsky

  • A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.

    Richard A. Larson;Richard K. Dodge;Charles A. Linker;Richard M. Stone

  • FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

    Susan P. Whitman;Amy S. Ruppert;Amy S. Ruppert;Michael D. Radmacher;Michael D. Radmacher;Krzysztof Mrózek

  • Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

    Guido Marcucci;Klaus H. Metzeler;Sebastian Schwind;Heiko Becker

Frequent Co-Authors

Clara D. Bloomfield
Clara D. Bloomfield The Ohio State University
Richard A. Larson
Richard A. Larson University of Chicago
Krzysztof Mrózek
Krzysztof Mrózek The Ohio State University
Richard Stone
Richard Stone Harvard University
Jonathan E. Kolitz
Jonathan E. Kolitz Hofstra University
Andrew J. Carroll
Andrew J. Carroll University of Alabama at Birmingham
Guido Marcucci
Guido Marcucci City Of Hope National Medical Center
Michael A. Caligiuri
Michael A. Caligiuri City Of Hope National Medical Center
Maria R. Baer
Maria R. Baer University of Maryland, Baltimore
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The medical field is vast, and there are many rewarding career paths beyond becoming a physician. Online degrees are growing in popularity for those seeking flexible routes into healthcare professions, including pharmacy, nursing, information management, and billing.

For students focused on cost, comparing online pharmacy school cost is essential, as programs can vary widely in tuition. Nursing is another high-demand career, and exploring the cheapest online fnp programs can help future family nurse practitioners enter the field affordably.

Not all healthcare roles are direct patient care. A health information technology online degree prepares students for the growing world of electronic health records, data security, and medical IT. Meanwhile, those interested in the administrative side of healthcare may find that medical billing and coding online courses offer a practical entry point with strong job prospects.

Exploring these online programs can open doors to diverse roles in medicine, whether your interests lie in clinical practice, technology, or healthcare management.

Best Scientists Citing Bayard L. Powell

Trending Scientists

Recently Published Articles